Skip to main content
Premium Trial:

Request an Annual Quote

GeneTraffic, JMV 1.0, BioCoRE, GeneCards 2.25, UDB 25

Premium

Iobion of San Diego has released version 2.0 of its GeneTraffic microarray data management and analysis software. The new release offers “start to finish” data analysis capability, according to Stephen Sharp, director of marketing. Users can import numerical two-color data files as well as image files from any scanner and move from data validation to graphical data representation and manipulation to cluster analysis, he said. GeneTraffic 2.0 uses graphical ActiveX components built on the OpenGL framework, which the company described as “a significant addition” to the software’s present web-based graphics capabilities.

The Theoretical Biophysics Group at the University of Illinois has released JMV 1.0, a Java-based molecular viewer, as part of BioCoRE (Biological Collaborative Research Environment), a freely accessible web-based collaboratory for biomedical research and training (http://www.ks.uiuc.edu/Research/BioCoRE). JMV is available at www.ks.uiuc.edu/Development/jmv. In addition, several other BioCoRE components have been updated.

 

The Weizmann Institute of Israel has released GeneCards 2.25 and UDB (Unified Database) 25 through its website, http://bioinformatics.weizmann.ac.il/cards.

Filed under

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.